In this study, we aimed to determine whether levels of prostate-specific kallikreins (total PSA, free PSA and hK2) measured in anti-coagulated plasma samples could predict locally advanced or metastatic prostate cancer up to 25 years before diagnosis. The gene discussed is KLK3; the disease is metastatic prostate carcinoma.